We are live on ! Find out more
CLYM

Climb Bio
CLYM

76 hedge funds and large institutions have $63.4M invested in Climb Bio in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 23

5% less funds holding

Funds holding: 80 → 76 (-4)

5.9% less ownership

Funds ownership: 82.87% → 76.97% (-5.9%)

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

37% less capital invested

Capital invested by funds: $100M → $63.4M (-$36.9M)

Holders
76
Holders Change
-4
Holders Change %
-5%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
23
Reduced
23
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$2.96M
2
CF
Cantor Fitzgerald
New York
+$2.19M
3
AAA
Affinity Asset Advisors
New York
+$1.62M
4
TCM
Tang Capital Management
California
+$1.62M
5
PLC
Peapod Lane Capital
New York
+$898K

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$5.72M
2
SB
Samsara BioCapital
California
-$4.7M
3
BCM
Boxer Capital Management
California
-$3.99M
4
Bank of America
Bank of America
North Carolina
-$1.62M
5
ABG
Ally Bridge Group
New York
-$1.37M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$38.3M – – –
BlackRock
2
BlackRock
New York
$2.8M -$15.9K -9,831 -0.4%
CF
3
Cantor Fitzgerald
New York
$2.44M +$2.19M +1,348,915 +207%
Citigroup
4
Citigroup
New York
$2.26M +$2.96M +1,827,387 +8,039%
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.83M -$6K -3,701 -0.2%
AAA
6
Affinity Asset Advisors
New York
$1.83M +$1.62M +1,000,000 +200%
KCM
7
Kynam Capital Management
New Jersey
$1.28M +$811K +500,000 +91%
DTC
8
Deep Track Capital
Connecticut
$1.27M – – –
TCM
9
Tang Capital Management
California
$1.22M +$1.62M +1,000,000 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$822K +$21.1K +12,980 +2%
DP
11
Diadema Partners
New Jersey
$817K +$479K +295,380 +79%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$716K -$69.6K -42,922 -7%
PLC
13
Peapod Lane Capital
New York
$676K +$898K +553,816 New
Renaissance Technologies
14
Renaissance Technologies
New York
$628K +$230K +142,098 +38%
NFGH
15
Nan Fung Group Holdings
Hong Kong
$566K – – –
SSA
16
Schonfeld Strategic Advisors
New York
$540K -$36.4K -22,439 -5%
UBS Group
17
UBS Group
Switzerland
$466K -$53.7K -33,130 -8%
State Street
18
State Street
Massachusetts
$462K – – –
JP Morgan Chase
19
JP Morgan Chase
New York
$374K +$23.7K +14,628 +5%
Northern Trust
20
Northern Trust
Illinois
$367K -$21K -12,952 -4%
Two Sigma Investments
21
Two Sigma Investments
New York
$311K +$28.2K +17,404 +7%
AI
22
Allostery Investments
Connecticut
$299K – – –
SFM
23
Sphera Funds Management
Israel
$295K -$16.2K -10,000 -4%
SC
24
Shay Capital
New York
$244K +$324K +200,000 New
Morgan Stanley
25
Morgan Stanley
New York
$216K -$80.9K -49,871 -22%
1
2 3 4

CLYM Hedge Fund Activity: Q1 2025 in Review

76 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q1 2025, worth a combined $63.4M — down 37% from $100M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CLYM and 10 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 23 added.

The largest buyer was Citigroup, adding an estimated $2.96M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $5.72M sold.

  • 76 institutional investors held Climb Bio (CLYM) as of Q1 2025, down from 80 in Q4 2024.
  • Funds reported $63.4M of Climb Bio stock for Q1 2025, down 37% quarter-over-quarter.
  • 10 funds opened new Climb Bio positions in Q1 2025 and 14 closed out, a net change of -4 holders.
  • The largest Climb Bio buyer in Q1 2025 was Citigroup, an estimated $2.96M added.
  • The largest Climb Bio seller in Q1 2025 was Janus Henderson Group, an estimated $5.72M sold.

Based on aggregated 13F filings for Q1 2025.